McQuade Center For Strategic Research & Development To Collaborate With Rugen Holdings To Develop Novel Treatment For Diverse Psychiatric Disorders

The McQuade Center for Strategic Research and Development, LLC (MSRD) announced today that it has entered an agreement with Rugen Holdings (Cayman) Limited, doing business as Rugen Therapeutics (Rugen). MSRD is a member of the global Otsuka family of pharmaceutical companies. Rugen Therapeutics a pre-clinical biotechnology company focused on the development of novel treatments for central nervous system (CNS) disorders.

The agreement will support the clinical development of therapeutics for patients living with a broad range of psychiatric disorders including treatment-resistant depression (TRD). Under the terms of the agreement, MSRD and Rugen will collaborate to advance Rugen’s . . .